MBIO Stock Summary and Trading Ideas (Mustang Bio | NASDAQ:MBIO)

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Mustang Bio trades on the NASDAQ stock market under the symbol MBIO.

As of November 13, 2026, MBIO stock price declined to $0.42 with 19,427 million shares trading.

MBIO has a beta of 1.51, meaning it tends to be more sensitive to market movements. MBIO has a correlation of 0.09 to the broad based SPY ETF.

MBIO has a market cap of $3.19 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, MBIO traded as high as $86.50 and as low as $.35.

The top ETF exchange traded funds that MBIO belongs to (by Net Assets): VXF.

MBIO has underperformed the market in the last year with a return of -66.3%, while the SPY ETF gained +11.5%. In the last 3 month period, MBIO fell short of the market, returning -30.4%, while SPY returned -2.1%. However, in the most recent 2 weeks MBIO has outperformed the stock market by returning +7.4%, while SPY returned -1.9%.

MBIO support price is $.43 and resistance is $.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MBIO shares will trade within this expected range on the day.